I-Mab Announces Upcoming Participation at September Conferences

Rhea-AI Summary

I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in several September conferences. Key events include the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, Jefferies Virtual Asia Forum on September 16, and the ICBCI Virtual ADR New Economy Conference on September 18, among others. Notable presenters include Dr. Jingwu Zang and Dr. Joan Huaqiong Shen, providing insights into the company's innovations in immuno-oncology and autoimmune diseases. I-Mab is focused on transitioning to a fully integrated global biopharmaceutical company.

Positive

• Participation in multiple prestigious conferences enhances visibility and investor interest.
• Management presentations by key leaders may strengthen stakeholder confidence.
• Company is transitioning toward full integration as a biopharmaceutical company.

Negative

• None.

SHANGHAI and GAITHERSBURG, Md., Sept. 8, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in September. Details of the conferences and management presentations are as follows:

Cantor Fitzgerald Virtual Global Healthcare Conference 2020
Presentation: Tuesday, September 15, 2020 at 8:00-8:30 a.m. ET
Presenters: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

Webcast link: https://www.webcaster4.com/Webcast/Page/2495/37179

The webcast will also be available under "Event Calendar" on IMAB's IR website at https://ir.i-mabbiopharma.com/

One-on-one meetings: September 15-17, 2020

For more information, please contact your Cantor Fitzgerald representative.

Jefferies Virtual Asia Forum
Presentation: Wednesday, September 16, 2020 at 4:00-4:50 a.m. ET
Presenters: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 14-16, 2020

For more information, please contact your Jefferies representative.

ICBCI Virtual ADR New Economy Conference
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 18, 2020

For more information, please contact your ICBCI representative.

2020 Huatai USA Autumn Virtual China Conference
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 21-23, 2020

For more information, please contact your Huatai representative.

Morgan Stanley Virtual Asia Pacific Conference
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: September 24-25, 2020

For more information, please contact your Morgan Stanley representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing, Shanghai, Hong Kong and Maryland, United States. For more information, please visit http://ir.i-mabbiopharma.com

For more information, please contact:

I-Mab

Jielun Zhu, CFO
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000

Gigi Feng, Vice President and Global Head of Corporate Communications
E-mail: gigi.feng@i-mabbiopharma.com
Office line: +86 21 6057 8000

Investor Inquiries:

Burns McClellan, Inc. (Americas and Europe)
Steve Klass
E-mail: sklass@burnsmc.com
Office line: +1 212 213 0006

The Piacente Group, Inc. (Asia)
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: +86 21 6039 8363

View original content to download multimedia:http://www.prnewswire.com/news-releases/i-mab-announces-upcoming-participation-at-september-conferences-301125446.html

SOURCE I-Mab

FAQ

What conferences is I-Mab participating in September 2020?

I-Mab is participating in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, Jefferies Virtual Asia Forum on September 16, and ICBCI Virtual ADR New Economy Conference on September 18, among others.

Who are the key presenters at I-Mab's upcoming conferences?

Key presenters include Dr. Jingwu Zang, Dr. Joan Huaqiong Shen, Mr. Jielun Zhu, and Ms. Leah Liu.

What is the focus of I-Mab's business?

I-Mab focuses on the discovery, development, and commercialization of novel biologics, particularly in immuno-oncology and autoimmune diseases.

What is the stock symbol for I-Mab?

The stock symbol for I-Mab is IMAB.

What is I-Mab's strategy for drug development?

I-Mab's strategy includes Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development through internal R&D and global partnerships.